Verified ProfileEN

Huazhong Pharmaceutical Company Limited

Order verification — $199

Manufacturing · Chemical Drug Raw Material Manufacturing

Verification dossier

Huazhong Pharmaceutical Company Limited is a Chinese company based in Xiangyang, Hubei. The company operates in the chemical drug raw material manufacturing sector, within the broader manufacturing industry. Established 2002, the company has been operating for 24 years.

Sinolinks tracks Huazhong Pharmaceutical Company Limited as part of our independent verification practice. The full 18-section verification report covers ownership, financial standing, regulatory standing, trade relationships, and operating credentials — reviewed by our Hong Kong-based expert and delivered in 24 hours.

Business scope

Drug production; contract drug manufacturing; drug import and export; drug wholesale; sales of drug-related precursor chemicals; drug retail; veterinary drug production; veterinary drug operation; food additive production; feed additive production; food production; health food production; feed production; road freight transport (excluding dangerous goods); public railway transport; inspection and testing services; production of ready-to-drink water; online information services for drugs; online information services for medical devices; production of dangerous chemicals; operation of dangerous chemicals; warehousing of dangerous chemicals.

Independent verification

Order the full verified report on this company

An 18-section verification report on this Chinese company, expert-reviewed and delivered in English within 24 hours. We support clients in six languages. HK-entity invoicing.

Order verification — $199

Independent verification

Included in the full report

Full Chinese legal name

Registration identifier

Legal representative & senior officers

Beneficial ownership & equity history

Registered address & operating premises

Capital & recent annual filings

Verified contact channels

Branches, controlled entities & investments

Trademark & patent portfolio

Trade relationships

Regulatory standing review